

## **Funding**

KS salary was supported by the Canadian Institute of Health Research through a Scientific Director's Grant (SOP 168483) to Dr. Brian Rowe. Funding for the publication costs of this manuscript was provided by the Department of Psychiatry at the University of Alberta.

## **Conflict of interest**

Author AK has received speaker/consultation fees from Lundbeck, Elvium, Pfizer, Otsuka, Takeda, Sunovion, Bausch Health, Novo Nordisk, Eisai, Jazz, Paladin, the Newly Institute and Abbvie. Author RM has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatrix, Abbvie, Atai Life Sciences and also he is a CEO of Braxia Scientific Corp. Author JS has received speaker/consultation fees from Abbvie, Eisai, Lundbeck, Bausch Health, Janssen, and serves as a medical advisor for the Newly Institute. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.